Unleash Immuno Oncolytics

What Unleash Immuno Oncolytics does

Unleash Immuno Oncolytics is a preclinical-stage, privately held biotechnology company developing an armed, conditionally replicating oncolytic virus platform designed to simultaneously target malignant cells and the tumor-associated stromal compartment. The company's core technology uses a proprietary SPARC promoter that drives selective viral replication in tumor microenvironment conditions such as inflammation and hypoxia, enabling physical disruption of tumor architecture and release of multiple virally produced cytokines that activate a systemic immune response against solid tumors. Its lead product candidate, UIO-524, is being advanced alongside two additional preclinical candidates, UIO-525 and UIO-526, all built on the same stroma-targeted adenoviral platform whose underlying science was licensed from Instituto Leloir in Argentina and Washington University in St. Louis.

The company is initially focused on muscle-invasive bladder cancer (MIBC) and other solid tumor indications characterized by dense stromal compartments that shield malignant cells from existing therapies. Unleash operates as a platform licensor rather than a clinical developer: in March 2026, it signed an exclusive worldwide royalty-free license with TransCode Therapeutics (NASDAQ: RNAZ) covering UIO-524, UIO-525, and UIO-526, with compensation structured entirely in equity (1,136,364 shares of non-voting convertible preferred stock representing 6.8% of TransCode's fully diluted common stock) rather than upfront cash or disclosed milestones. The company was founded in 2015, incubated at BioGenerator in St. Louis, and is backed by BioGenerator, Draper Cygnus, Dragones Ventures, Axia Ventures, and Oncolys Biopharma.

Commercially, Unleash generates no product revenue and has 1-10 employees. Its economic model is built on licensing the underlying platform IP to larger pharmaceutical or biotech partners who fund clinical development and commercialization, with the TransCode transaction representing both its first and only disclosed commercial agreement to date.

Name

Unleash Immuno Oncolytics

Legal name

Unleash Immuno Oncolytics, Inc.

Website

https://unleash.bio

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Unleash Immuno Oncolytics is a preclinical-stage biotech developing armed, stroma-targeted oncolytic viruses using a proprietary SPARC promoter to treat solid tumors, with all three pipeline candidates licensed to TransCode Therapeutics.

Ownership category

akta.pro rank

Product category

Immuno-Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

akta.pro secondary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

Keywords

• Oncolytic virus therapy
• Cancer immunotherapy
• Stroma-targeted oncolytics
• Oncolytic virus platform
• Immuno-oncology drugs

Headquarters

HQ city

Fenton

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Licensing and Milestone Payments: Unleash licenses its technology platform to pharmaceutical partners in exchange for equity stakes and potential milestone payments. In the TransCode transaction, the company received 1,136,364 shares of non-voting convertible preferred stock representing 6.8% of TransCode's fully diluted common stock.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Unleash Immuno Oncolytics develops an armed, conditionally replicating oncolytic virus platform that targets both malignant cells and tumor-associated stroma cells. Its lead candidate UIO-524 uses a proprietary SPARC promoter for tumor-microenvironment-activated viral replication, and is armed with multiple cytokines to physically disrupt tumor architecture and unleash a systemic immune response against solid tumors. The company licenses its preclinical candidates (UIO-524, UIO-525, UIO-526) to larger pharmaceutical and biotech partners for clinical development and commercialization.

Product overview

Unleash Immuno Oncolytics is an immune-oncology company developing an armed, oncolytic virus platform that targets both tumor cells and the stromal compartment through multiple mechanisms of action in a single product. The platform uses conditionally replicating viruses with proprietary SPARC promoter-driven replication that is enhanced in tumor microenvironment conditions (inflammation and hypoxia). The lead product UIO-524 combines viral replication with multiple cytokines to physically disrupt tumor architecture and unleash systemic immune response. Additional pipeline candidates UIO-525 and UIO-526 are also part of the platform targeting solid tumors. In March 2026, the company licensed UIO-524, UIO-525, and UIO-526 to TransCode Therapeutics in an all-stock transaction.

Differentiator

Problem solved

Functional benefit

Products and services

• UIO-524 Lead armed, conditionally replicating oncolytic virus designed to target both malignant cells and tumor-associated stroma cells. Uses the proprietary SPARC promoter for tumor-microenvironment-activated viral replication and is armed with multiple virally produced cytokines that modulate the immune defenses to unleash a systemic immune response against solid tumors, with initial focus on muscle-invasive bladder cancer.
• UIO-525 Preclinical oncolytic immunotherapy drug candidate targeting solid tumors, part of the next-generation adenovirus platform developed by Unleash and licensed to TransCode Therapeutics.
• UIO-526 Preclinical oncolytic immunotherapy drug candidate targeting solid tumors, part of the next-generation adenovirus platform developed by Unleash and licensed to TransCode Therapeutics.
• Stroma-Targeted Armed Oncolytic Virus Platform Next-generation oncolytic virus platform utilizing proprietary SPARC promoter technology to develop armed viruses that target both tumor cells and the stromal compartment through multiple mechanisms of action in a single product. Enables infection throughout the entire tumor mass combined with virally produced cytokine modulators to activate immune response against solid tumors.

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered flagship, core and minor.

• TransCode TherapeuticsflagshipStrategic or Co-development Partner · 1 March 2026Exclusive worldwide, fully paid-up royalty-free license agreement for three preclinical drug candidates (UIO-524, UIO-525, UIO-526) targeting solid tumors with initial focus on muscle-invasive bladder cancer. Unleash received 1,136,364 shares of non-voting convertible preferred stock representing 6.8% of TransCode's fully diluted common stock.
• Instituto LeloircoreTechnology or IntegrationTechnology licensed from Instituto Leloir in Argentina as foundation for Unleash's oncolytic virus platform development.
• Washington University in St. LouiscoreTechnology or IntegrationTechnology licensed from Washington University in St. Louis as foundation for Unleash's next-generation oncolytic virus platform.
• Tungsten AdvisorsminorOthersActed as the exclusive financial advisor for the TransCode licensing transaction.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• PsiOxus Therapeutics: Clinical-stage biotech developing the oncolytic virus enadenotucirev (now NG-348, NG-641) for solid tumors. Comparable in developing tumor-microenvironment-targeting, armed oncolytic virus platforms for solid tumor indications.
• Cold Genesys: Clinical-stage immuno-oncology company developing oncolytic virus therapies (e.g., CG0070 for NMIBC) using proprietary adenovirus platforms. Comparable in platform technology and in focusing on bladder cancer, a key initial indication for Unleash's UIO-524.
• DNAtrix: Clinical-stage oncolytic virus company developing virus-based therapies for brain tumors. Highly comparable — Unleash's CSO Imre Kovesdi was previously CSO of DNAtrix after its merger with Vectorlogics, indicating direct lineage and similar adenovirus-based therapeutic approach.
• GenVec: Gene therapy company developing virus-based therapeutics using adenoviral and other viral vectors. Closely comparable technology stack — Unleash's CSO Imre Kovesdi was previously CSO of GenVec — and overlapping scientific leadership in viral vector oncology.
• Replimune: Clinical-stage oncolytic immunotherapy company developing a proprietary platform (RP1, RP2, RP3) using armed oncolytic viruses for solid tumors. Most directly comparable listed peer in terms of platform approach (armed oncolytic viruses) and indication focus.
• Vyriad: Clinical-stage oncolytic virotherapy company developing engineered vesicular stomatitis and measles virus platforms (e.g., Voyager-V1). Comparable as an emerging player in armed/engineered oncolytic virus approaches for solid tumors.

Emerging players

• Targovax: Clinical-stage immuno-oncology company developing oncolytic viruses (ONCOS-102) and peptide vaccines for solid tumors. Comparable indication focus (solid tumor immunotherapy) and platform-adjacent therapeutic category.
• Oncolys BioPharma: Japanese-listed biotech developing oncolytic virus and exosome-based cancer therapies. Comparable as an oncology virus-therapy specialist, and a direct relationship to Unleash via its 2018 lead investment.
• Lokon Pharma: Early-stage company developing armed oncolytic adenoviruses with cytokine expression for solid tumor treatment. Closely comparable to Unleash's multi-cytokine armed adenovirus platform with similar mechanistic rationale.

Broad incumbents

• TransCode Therapeutics: Clinical-stage RNA oncology company (NASDAQ: RNAZ) that has exclusively licensed UIO-524/525/526 from Unleash. Comparable as the entity now advancing the licensed oncology assets, with overlapping exposure to the same candidates and indication (MIBC).

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/UnleashBIO
• Facebookfacebook.com/UnleashBio

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Unleash Immuno Oncolytics